Citation Impact
Citing Papers
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects
2004
Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
2003
ErbB Receptors: Directing Key Signaling Networks Throughout Life
2004
Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation
2004
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
2003
Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy
2003
EGFR associated expression profiles vary with breast tumor subtype
2007
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
2001
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Tumor Engineering: Orthotopic Cancer Models in Mice Using Cell-Loaded, Injectable, Cross-Linked Hyaluronan-Derived Hydrogels
2007
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
ErbB-targeted therapeutic approaches in human cancer
2003
Hyaluronic Acid Hydrogels for Biomedical Applications
2011 Standout
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
2009 Standout
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Comparing antibody and small-molecule therapies for cancer
2006
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Issues and progress with protein kinase inhibitors for cancer treatment
2003
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
2003 Standout
Molecular mechanisms of drug resistance
2005
Dissemination and growth of cancer cells in metastatic sites
2002 Standout
Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines
2009
Lung Cancer
2008 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Epidermal Growth Factor Receptor Targeting in Cancer
2006
Head and neck cancer
2008 Standout
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
The type III epidermal growth factor receptor mutation
2001
Proliferation, cell cycle and apoptosis in cancer
2001 StandoutNature
New approaches for mesothelioma: Biologics, vaccines, gene therapy, and other novel agents
2002
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
2001 Standout
Anticancer therapy targeting the erbB family of receptor tyrosine kinases
2001
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
2012 StandoutNature
From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents
2000
Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells
2002 StandoutNobel
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs
2003
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma
2004
Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer
2005
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
Gefitinib — a novel targeted approach to treating cancer
2004
Targeting epidermal growth factor receptor—are we missing the mark?
2003
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Erlotinib (Tarceva®): a promising drug targeting epidermal growth factor receptor tyrosine kinase
2003
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Revealing the world of RNA interference
2004 StandoutNatureNobel
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
2002
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
‘Targeting’ the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa®) in non-small cell lung cancer (NSCLC)
2004
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Epidermal growth factor receptor inhibitors in clinical development
2004
Ras, PI(3)K and mTOR signalling controls tumour cell growth
2006 StandoutNature
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors
2003
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Gefitinib (ZD1839, Iressa®) in non‐small‐cell lung cancer: a review of clinical trials from a daily practice perspective
2005
Challenges in the treatment of bladder cancer
2006
Gefitinib for non-small-cell lung cancer treatment
2011
Identification of Cyclobutane Pyrimidine Dimer-Responsive Genes Using UVB-Irradiated Human Keratinocytes Transfected with In Vitro-Synthesized Photolyase mRNA
2015 StandoutNobel
Advances in Malignant Mesothelioma
2005 Standout
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
Tumorigenesis and the angiogenic switch
2003 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Constituents from Salvia Species and Their Biological Activities
2012 Standout
Catalytic Enantioselective Desymmetrization Reactions to All-Carbon Quaternary Stereocenters
2016
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
2004
BindingDB Entry 50022499: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
2025
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.
2003
ZD1839 Modulates Paclitaxel Response in Renal Cancer by Blocking Paclitaxel-Induced Activation of the Epidermal Growth Factor Receptor–Extracellular Signal-Regulated Kinase Pathway
2004
Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial
2002
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
2001
IncreasedHER2Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients
2005
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
2001
Progress in the Delivery of Therapeutic Oligonucleotides: Organ/Cellular Distribution and Targeted Delivery of OligonucleotidesIn Vivo
2003
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
2013 Standout
Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition
2002
Di- and triterpenoids of Salvia pomifera
1994
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
2005
Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
2007
Recent Advances in Stereoselective Synthesis and Application of β-Amino Acids
2009
Molecular correlates of gefitinib responsiveness in human bladder cancer cells
2007
Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis.
2003
Terpenoids from Salvia mellifera
1990
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy
2004
Cancer Genome Landscapes
2013 StandoutScience
Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy
2007
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
2009 StandoutScience
Disulfonimide-Catalyzed Asymmetric Synthesis of β3-Amino Esters Directly from N-Boc-Amino Sulfones
2013 StandoutNobel
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
2003
Strong and Confined Acids Control Five Stereogenic Centers in Catalytic Asymmetric Diels–Alder Reactions of Cyclohexadienones with Cyclopentadiene
2020 StandoutNobel
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
2003
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.
2003
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
2002
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
2004 Standout
Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins
2001
Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy
2005
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
2004
Works of R. Caputo being referenced
Enantiopure β3-amino acids-2,2-d2 via homologation of proteinogenic α-amino acids
2006
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.
2001
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
2000
Synthesis of marrubiin
1972
Neutral triterpenes from the galls of Pistacia terebinthus
1973